"The ability of GX15-070 to inhibit tumor progression and also enhance the effects of other treatment modalities that often suffer from resistance is encouraging," stated Gordon Shore, Ph.D., Chief Scientific Officer of Gemin X. "This study describes the novel activity of this compound and supports its therapeutic use in diverse cancer types, including multiple myeloma."
In the preclinical studies, GX15-070 potently inhibited the viability of 15 of 16 human myeloma cell lines (HMCLs), including those resistant to treatment with melphalan (a chemotherapeutic) and dexamethasone (a corticosteroid). Combination studies with GX15-070 demonstrated that it enhanced the anti-myeloma activity stimulated by melphalan, dexamethasone, and bortezomib, a proteosome inhibitor. Additionally, single-agent studies of the candidate showed that it induced potent cytotoxic responses against patient-derived tumor cells without inducing cytotoxicity to human blood lymphocytes.
Gemin X is currently conducting several clinical trials of GX15-070 in multiple cancer types as a combination therapy and as a single agent. Gemin X recently initiated a Phase 1 trial with GX15-070 in combination with bortezomib in patients with mantle cell lymphoma (MCL) and a Phase 1/2 clinical trial in combination with docetaxel in patients with non-small cell lung cancer. G X15-070 is also in Phase 2 clinical trials in patients with Hodgkin's Lymphoma and in myelofibrosis with myeloid metaplasia. In multiple Phase 1 studies, GX15-070 was well-tolerated and resulted in clinical and biological activity.
The study, which is currently available in the online edition Blood, is titled, "Pre-clinical studies of the pan-Bcl inhibitor obatoclax (GX15-070) in multiple myeloma," was led by Dr. Suzanne Trudel, et al., of the Mayo Clinic of Medicine, Scottsdale, AZ, and Princess Margaret Hospital, Toronto, ON. The report will also appear in the print edition of Blood.
About Multiple Myeloma (MM)
Multiple myeloma is a type of cancer caused by malignant plasma cells that are spread throughout the bone marrow, resulting in bone erosion and interference with bone marrow and immune system function. MM is incurable and is characterized by frequent early responses to treatment followed by relapse. The American Cancer Society estimates that nearly 11,000 Americans will die of MM in 2007, and the 5-year survival rate for the disease is approximately 33 percent.
Gemin X Biotechnologies Inc. specializes in the discovery and development of novel small molecule cancer therapeutics based on the regulation of apoptosis, the body's natural ability to destroy injured or damaged cells. Gemin X's lead product, GX15-070, is a small molecule, pan-inhibitor of Bcl-2 proteins and is currently in Phase 2 clinical trials. Gemin X is also developing a small molecule that induces apoptosis in p53-defective cancers. Gemin X is privately held and is located in Montreal, Quebec and Malvern, Pennsylvania. For additional information please visit Gemin X at www.geminx.com
MacDougall Biomedical Communications
Jennifer Greenleaf, 508-647-0209
Gemin X Biotechnologies
Sherri Carenzo, 610-640-5735 Ext. 16